巴里

educator

[巴里 @bstocks7]

SPONSORED

SPONSORED
🔥 Nasdaq: $DGNX — TINY 14.45M FLOAT + $150M RESULTICKS REVENUE + $100M+ M&A BLITZ! AFTERNOON BREAKOUT WATCH? 💥🚀

• 📉💥 Tiny float of 14.45M shares (42.34% insider-ownership) + microcap valuation vs enterprise-scale pro-forma business could create explosive re-rating setup on our hands (Source: https://t.co/4JvpN795uh) ⚡

• 📈🚀 Just last month $DGNX had a multi-day surge from $1.11 to a high of $1.90 (gain of over +70%) in JUST 4 days — could we see history repeat itself this week? (Source: https://t.co/BWwfkACKtv) 🔥

• 💰🛡️ Debt-free M&A blitz — the company reports no debt and over $100M+ in completed M&A deployed across Matter DK and Remedy, Plan A... The company's founder injected $25.4M of equity investment at about 4.7x current price (Source: https://t.co/64bWywE1Gm) 💥

• 🤝📊 Synergies already live — February 2026 reseller agreement targets US$40M in cumulative revenues over four years for Diginex's sustainable RegTech business... With Diginex's Chairman & Founder adding that "this transaction will deeply enhance the company's expertise in AI and data management" (Source: https://t.co/WergOdeqJf) 🚀

• 💰🌍 Revenue explosion — Resulticks adds ~$150M CY2025 revenue + $46M EBITDA, pushing revenue projections to between US$190M - US$210M in FY2026, and to US$250 - US$280M in FY2027 ! (Source: https://t.co/bLxcidxt1O) 💥

Disclaimer: https://t.co/fPNEsMxqyd

[巴里 @bstocks7]

1PM EST.

[巴里 @bstocks7]

SPONSORED

🔥 Nasdaq: $OPTH — LOW FLOAT ~3.41M + GMP PSILOCYBIN PRODUCTION + DIAMOND EQUITY COVERAGE! SHORT-SQUEEZE SETUP! 💥🚀

• 📉💥 Low float of roughly 3.41M shares creates explosive asymmetric volatility potential on any positive catalyst (Source: https://t.co/LB8dO1zs9x) ⚡

• 📰🚀 Completes commercial GMP psilocybin production run — 5mg capsules now prescribed for treatment-resistant depression in Australia, with surplus earmarked for US and European clinical trials; bottling configuration improved for clinicians and patients (Source: https://t.co/XYZEsZmYUm) 🔥

• 🌍💊 Australia regulatory expansion broadens eligible therapy teams, expands treatment settings beyond hospitals, improves rural/regional access, and opens reimbursement opportunities across public and private payers (Source: https://t.co/6qWek9IhvO) 🚀

Disclaimer: https://t.co/f9XYfZn010

[巴里 @bstocks7]

SPONSORED

🔥 Nasdaq: $GOAI — 25% EQUITY + $20M IN SPIRO SENIOR CARE! AI ENGINE FOR $1.3T SENIOR‑CARE INDUSTRY! 💥🚀

• 📉💥 LOW-FLOAT setup so asymmetric it feels like a glitch in the matrix — GOAI locks in 25% of Spiro Senior Care and commits up to $20M to fuel rapid AI‑driven senior care platform (Source: https://t.co/uJvAteXf9i) ⚡

• 🧠💰 AI Treat‑in‑Place Healthcare System — Predictive analytics, real‑time health insights, coordinated communication tools, and personalized wellness programs could turn GOAI into the core operating system for senior care (Source: https://t.co/uJvAteXf9i) 🔥

• 🏥🚀 Meridian Senior = Instant National Scale — Backed by an operator of 40+ communities across 16+ states serving 7,000+ residents, with 4 Spiro facilities launching now (Source: https://t.co/uJvAteXf9i) 💥

• 🤖🛡️ Proven AI Moat — Spiro selected GOAI’s battle‑tested AI stack (Eva Brain, NeuroServe) to power care coordination, cognitive health, and automation (Source: https://t.co/uJvAteXf9i) 🚀

Disclaimer: https://t.co/71j4AlQoMP

[巴里 @bstocks7]

9:30AM EST.

[巴里 @bstocks7]

9:30AM EST.

[巴里 @bstocks7]

SPONSORED

$ADTX double

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million (source: https://t.co/QpvwCgfwxN)

Disclaimer: https://t.co/T3ldpviFUD

[巴里 @bstocks7]

SPONSORED
🔥 Nasdaq: $ADTX — ULTRA LOW FLOAT ~816K + IGNITE PROTEOMICS 10K PATIENT REGISTRY + DANA-FARBER STUDY! 💥🚀

• 📉💥 Ultra-low float of roughly 816K shares creates massive asymmetric volatility potential on any demand shift (Source: https://t.co/E8o8pxY8tl) ⚡

• 📰🔬 Ignite Proteomics launches prospective 10,000-patient oncology registry to evaluate functional proteomics in cancer therapy selection across ADC and immunotherapy regimens — expected ~$13M revenue contribution (Source: https://t.co/EzcQHb5tnJ) 🔥

• 👔💰 Appoints Jeffrey M. Busch as Interim CEO — founder and former CEO of $1B NYSE enterprise with ~8.5% dividend track record; also leads Ignite Proteomics for tighter execution alignment (Source: https://t.co/smQLhpImz8) 🚀

• 📊🧪 Dana-Farber study demonstrates predictive value of Ignite’s RPPA platform for T-DXd (Enhertu®) in metastatic breast cancer — outperformed standard HER2 IHC in key cohorts (Source: https://t.co/1uWMBoa3gb) 💥

• 🛡️🏥 CLIA-certified precision oncology lab via Ignite Proteomics acquisition using RPPA technology for functional proteomics therapy selection — collaborations with Dana-Farber, Vanderbilt, and other NCI centers (Source: https://t.co/W1CM3IWkpl) 🛡️

Disclaimer: https://t.co/4RQlN8MR48

[巴里 @bstocks7]

SPONSORED
🔥 Nasdaq: $ADTX — ULTRA LOW FLOAT ~816K + IGNITE PROTEOMICS 10K PATIENT REGISTRY + DANA-FARBER STUDY! 💥🚀

• 📉💥 Ultra-low float of roughly 816K shares creates massive asymmetric volatility potential on any demand shift (Source: https://t.co/E8o8pxY8tl) ⚡

• 📰🔬 Ignite Proteomics launches prospective 10,000-patient oncology registry to evaluate functional proteomics in cancer therapy selection across ADC and immunotherapy regimens — expected ~$13M revenue contribution (Source: https://t.co/EzcQHb5tnJ) 🔥

• 👔💰 Appoints Jeffrey M. Busch as Interim CEO — founder and former CEO of $1B NYSE enterprise with ~8.5% dividend track record; also leads Ignite Proteomics for tighter execution alignment (Source: https://t.co/smQLhpImz8) 🚀

• 📊🧪 Dana-Farber study demonstrates predictive value of Ignite’s RPPA platform for T-DXd (Enhertu®) in metastatic breast cancer — outperformed standard HER2 IHC in key cohorts (Source: https://t.co/1uWMBoa3gb) 💥

• 🛡️🏥 CLIA-certified precision oncology lab via Ignite Proteomics acquisition using RPPA technology for functional proteomics therapy selection — collaborations with Dana-Farber, Vanderbilt, and other NCI centers (Source: https://t.co/W1CM3IWkpl) 🛡️

Disclaimer: https://t.co/4RQlN8MR48

[巴里 @bstocks7]

7:45am EST.

[巴里 @bstocks7]

7:45am EST.

[巴里 @bstocks7]

SPONSORED
🔥 RE-ALERT: Nasdaq: $VWAV — EUROSATORY 2026 DEBUT + FORESIGHT INVESTMENT + LOW FLOAT 18.58M! AFTERNOON BREAKOUT WATCH? 💥🚀

• 📉💥 Low float of roughly 18.58M shares creates heightened volatility potential on any positive catalyst flow (Source: https://t.co/0tEKeajTst) ⚡

• 📰🚀 First large-scale public presentation at Eurosatory 2026 in Paris — expanding to full public exhibition, live demos, and technical briefings to showcase integrated expeditionary autonomy ecosystem (Source: https://t.co/G1XHWjpeY1) 🔥

• 🤝💰 Strategic investment in Foresight Autonomous Holdings (up to 51%) + integration with xClibre™ AI Video Intelligence platform to build three-layer counter-UAS and multi-domain sensing stack (Source: https://t.co/jzyyEHd6gB) 🚀

• 📈🌍 Foresight moves to serial production with $10.5M potential revenue pipeline in Japan for ADAS systems under high-margin software license model — direct upside for VWAV stake (Source: https://t.co/9RMuKqphrT) 💥

• 📊🧠 Zacks Small-Cap Research initiates coverage highlighting AI-driven autonomy, advanced RF + vision-based sensing, real-time situational awareness, and strong 2026+ revenue growth outlook across air, land, and sea domains (Source: https://t.co/BQZTyBurXL) 🛡️

Disclaimer: https://t.co/xBjO0pOAsV

[巴里 @bstocks7]

SPONSORED

🔥 Nasdaq: $OPTH — LOW FLOAT ~3.41M + GMP PSILOCYBIN PRODUCTION + DIAMOND EQUITY COVERAGE! SHORT-SQUEEZE SETUP! 💥🚀

• 📉💥 Low float of roughly 3.41M shares creates explosive asymmetric volatility potential on any positive catalyst (Source: https://t.co/LB8dO1zs9x) ⚡

• 📰🚀 Completes commercial GMP psilocybin production run — 5mg capsules now prescribed for treatment-resistant depression in Australia, with surplus earmarked for US and European clinical trials; bottling configuration improved for clinicians and patients (Source: https://t.co/XYZEsZmYUm) 🔥

• 🌍💊 Australia regulatory expansion broadens eligible therapy teams, expands treatment settings beyond hospitals, improves rural/regional access, and opens reimbursement opportunities across public and private payers (Source: https://t.co/6qWek9IhvO) 🚀

• 📊💰 Diamond Equity Research initiates coverage highlighting high-margin GMP infrastructure, significant unused production capacity, clear path to profitability with low patient volumes, and asset-light strategy reducing clinical risk (Source: https://t.co/IFVSDo1nlb) 💥

• 🧪🌿 Achieves 6% naturally derived psilocybin extract — highest-purity botanical extract to date using proprietary genetics library; strengthens product consistency for Australia programs and supports upcoming European clinical research (Source: https://t.co/hp6hRo55ki) 🛡️

Disclaimer:
https://t.co/Xyv6AHhsFK

[巴里 @bstocks7]

do i kms?

[巴里 @bstocks7]

8AM EST.

[巴里 @bstocks7]

8AM EST.

[巴里 @bstocks7]

SPONSORED
🔥 Nasdaq: $SURG — LOW FLOAT <18M + Q1 REVENUE +51% + ALPHA CASH 25K PILOT! 9,000 CORNER STORES AI PLATFORM! 💥🚀

• 📉💥 Float less than 18M shares available to the public — potential for big moves if demand begins to shift (Source: https://t.co/qiuRF5ceIM) ⚡

• 📰💰 Q1 2026 Revenue approximately $16M, up roughly 51% year-over-year driven by Point-of-Sale and Prepaid Services growth of approximately 71%; G&A expenses dropped approximately 25% year-over-year to about $3.5M (Source: https://t.co/sAhSI81iuV) 🚀

• 🏪🔥 Closed six new wholesale distribution partners (three Master Agent agreements covering over 3,000 retail locations and three independent sales organization agreements); launched fully integrated stored value and loyalty platform plus Managed Marketing Services platform (Source: https://t.co/sAhSI81iuV) 💥

• 📱💰 25,000-activation pilot with Alpha Modus to launch Alpha Cash mobile wallet across distribution network — $10 bounty per activation, $250,000 pool, 10% revenue share, five-year tail; initial activations expected by July 1, 2026 (Source: https://t.co/fWdvlHrUk5) ⚡

• 🤖🌍 Advancing real-time AI decisioning platform built on https://t.co/ouphtBKocl™ and nationwide retail network; HERO™ MVNE platform signed wholesale contracts with multiple MVNO/MVNE customers with wholesale wireless revenue contribution anticipated in Q3 2026 results (Source: https://t.co/sAhSI81iuV) 🛡️

Disclaimer: https://t.co/K6zmdqqVqf

[巴里 @bstocks7]

9:30AM EST.

[巴里 @bstocks7]

9:30AM EST.

[巴里 @bstocks7]

SPONSORED

🔥 Nasdaq: $TDTH — TINY 3.57M SHARE FLOAT + TDTHAI AI LAUNCH + $800M GHANA JV! AFRICA STABLECOIN CATALYST! 💥🚀

• 📉💥 Ultra-low ~3.57M shares outstanding creates massive asymmetric volatility potential on any positive catalyst flow (Source: https://t.co/Vv3qI8xu70) ⚡

• 📰🚀 Major new catalyst: Launches TDTHAI AI platform across Asia-Pacific to accelerate enterprise AI deployment, automation & digital infrastructure growth (Source: https://t.co/Xxob1rriVM) 🔥

• 🌍💰 Strategic Ripple cooperation agreement to co-build stablecoin payment system for Africa market using Ripple USD (RLUSD) technology (Source: https://t.co/Qh4w0es6Wd) ⚡

• 🏗️💥 Ghana JV targets up to $800M combined revenue in first 5 years — driving government-led digital citizen & fintech infrastructure transformation (Source: https://t.co/bDxCYUr3Uo) 🚀

• 🛡️🤖 Memcyco partnership launches Asia-Pacific’s first preemptive AI fraud defense — blockchain identity meets real-time deception intelligence to intercept fraud before it hits (Source: https://t.co/qQxKhK439M) 💥

Disclaimer: https://t.co/N6EONbnoAc

[巴里 @bstocks7]

11AM EST.

(yes 17mins)

[巴里 @bstocks7]

11AM EST.

(yes 17mins)

[巴里 @bstocks7]

Disseminated on Behalf of Boxabl Inc.
$FGMC
PLEASE NOTE: THE PROPOSED MERGER IS NOT CLOSED YET, COMPLETION OF THE PROPOSED MERGER IS SUBJECT TO THE APPROVAL OF THE PROPOSED MERGER BY THE COMPANIES' STOCKHOLDERS AND OTHER CLOSING CONDITIONS AND thus there is no guarantee that it will close.

SPONSORED
Next-Gen Tech Spotlight: See Why ($FGMC) Hit Today’s Watchlist

*Sponsored by BOXABL Inc. Recent SEC Filings Provide Updates on (FGMC) Proposed Merger FG Merger II Corp. (FGMC) is at the Top of Our Watchlist for Today — Thursday, June 4, 2026

• A technology-driven company operating in one of America’s most strategically important and supply-constrained industries has entered into a merger agreement aimed at securing a NASDAQ public listing. If the merger closes, the combined entity would represent a publicly accessible company operating in the manufactured housing technology space.

• FG Merger II Corp. (FGMC) is a special purpose acquisition company currently in the final stages of a PROPOSED MERGER that, if completed, would bring BOXABL, Inc., a housing technology company, into the public markets. The company announced that the U.S. Securities and Exchange Commission ( "SEC") has declared effective the companies' joint registration statement on Form S-4 in connection with their previously announced PROPOSED MERGER. A shareholder meeting to approve the PROPOSED MERGER is scheduled for June 9, 2026, and the transaction is expected to close shortly thereafter. At that time, (FGMC) is slated to become BOXABL under the ticker BXBL. That means the potential ticker change is just days away…

• BOXABL has spent years building momentum. It has established a level of consumer awareness through social media (over 750M views across platforms) and accumulated more than 200,000 customer inquiries through its website since its founding in 2017. The company’s sizable following and upcoming potential catalysts related to the PROPOSED MERGER have caught our attention. And that is just the beginning of the reasons why (FGMC) will be topping our watchlist this morning— Thursday June 4, 2026

• Building the Future of Housing — Without Contractors or Carpenters BOXABL is a Nevada-based housing technology company with a mission to fundamentally change how homes are designed, manufactured, and deployed. The company makes modular, foldable residential units that can be transported on standard trailers and quickly assembled on-site. Where traditional homebuilders depend on weather-exposed job sites, fragmented labor, and months-long timelines, BOXABL builds its units entirely on its factory floor. It’s more like a smartphone assembly line than a construction site. Homes are engineered as a repeatable, scalable manufactured product rather than a one-off construction project. At the center of BOXABL's commercial lineup is the Casita, a foldable, factory-built dwelling unit designed to be shipped on a standard flatbed truck and deployed in a matter of hours. The original Casita — the one most people think of when they hear the name — started out as a 19 ft. x 19 ft. studio home complete with a living/sleeping area, full kitchen with standard appliances and a full bathroom. The company has since expanded the platform into additional configurations, including multi-bedroom layouts. Its Phase 2 Modular Building System, currently in prototype stage, contemplates floorplans as large as 2,400 sq. ft. It has also developed the Baby Box, a 120 sq. ft. unit built to RV standards for less complex installations. BOXABL's manufacturing model is built around a single core insight: that the construction industry is one of the least automated industries in the modern economy, and that applying factory-floor precision to home production has the potential to dramatically reduce cost, improve quality, and compress delivery timelines in ways that traditional builders structurally cannot match. This is especially important now, with American housing under structural stress. A scalable factory-built solution could be positioned to address what the company estimates is a deficit of over 4M homes, with elevated real estate costs impacting 75% of potential homebuyers. The company reports more than 200,000 potential customer inquiries through its website since 2017. As of December 31, 2025, BOXABL held customer deposits of $3.6M from approximately 7,818 potential customers. BOXABL’s PROPOSED MERGER with (FGMC) is intended to provide BOXABL with access to the public capital markets and is expected to provide the Combined Company with enhanced access to capital. Scaling up is a crucial step toward the goal of increasing production capacity to a level that begins to address the supply side of the U.S. housing shortage in a meaningful way.

• Developments That Could Grab Analysts’ Attention SEC Declares S-4 Registration Statement Effective: The SEC has declared the companies' Form S-4 registration statement effective, marking a critical regulatory milestone and clearing the path to a shareholder vote and potential close. Shareholder Meeting Scheduled for June 9, 2026: Shareholders of both companies are expected to vote on the PROPOSED MERGER on June 9, 2026. That places the transaction timeline in weeks. Transaction Expected to Close Shortly After Shareholder Approval: Subject to customary closing conditions, the PROPOSED MERGER is expected to close shortly after the June 9 vote, transitioning (FGMC) into an operating company under the BXBL ticker. Reduced Inspection Requirements in California: After working closely with California’s Housing and Community Development, BOXABL announced in Q3 2025 that only 25% of Casita Studios shipped to California will require state inspection. This streamlines the delivery process for units shipped to California. New revenue streams in development: The company’s business model extends beyond unit sales alone. Management has discussed developing ancillary service revenue opp’s tied to financing, insurance, maintenance and installation services. That approach could provide higher-margin recurring revenue streams alongside home production.

Disclaimer: https://t.co/HsUnkuG5Uu

[巴里 @bstocks7]

9:30 AM EST.

[巴里 @bstocks7]

9:30 AM EST.

[巴里 @bstocks7]

SPONSORED

🔥 RE-ALERT: Nasdaq: $MDCX — NEW HIGHS $0.3850 ON REGISTRATIONAL PR! LOW FLOAT 9.63M SHARES — BREAKOUT TO NEW DAY HIGH POSSIBLE? 💥🚀

• 📈💥 Exploded to fresh highs of $0.3850 this morning after the open on the strong registrational development PR — momentum accelerating with more attention turning to the news (Source: https://t.co/YGJ3GzVWb1) ⚡

• 📰🚀 Major catalyst: Advances SkinJect® into registrational Phase 2b (SKNJCT-005) for Gorlin Syndrome — up to 50 patients, primary endpoint complete clearance in ≥50% of target lesions at Week 10 (Source: https://t.co/1gkO6Xdy1S) 🔥

• 👀💣 Fairly small float of only 9.63M shares + change in demand creates explosive asymmetric setup — could this fuel a breakout to new high of the day? (Source: https://t.co/owsRzijYNR) 💥

• 🔬💰 $22M non-dilutive financing secured (pro forma cash ~$30M, >24-month runway, zero dilution) + prior Phase 2 data (55% histologic CR / 64% clinical clearance) gives full runway for this registrational push (Source: https://t.co/0mn5AFErOh) 🚀

• 🎯🌍 Watching for new high of the day breakout — 52-week high at $3.69 from current levels; low float + fresh catalyst momentum could drive significant move if volume sustains (Source: https://t.co/PG8WMKjIzZ) 🛡️

Disclaimer: https://t.co/5O5iV25rod

[巴里 @bstocks7]

SPONSORED

🔥 MARKET OPEN ALERT: Nasdaq: $MDCX — PRE-MARKET HIGH $0.35 ON REGISTRATIONAL PR! 50-DAY MA $0.36 BREAKOUT WATCH! 💥🚀

• 📈💥 Surged to fresh pre-market high of $0.35 on this morning’s strong registrational development PR — momentum building fast with more eyeballs turning to the news (Source: https://t.co/YGJ3GzVWb1) ⚡

• 📰🚀 Major catalyst: Advances SkinJect® into registrational Phase 2b (SKNJCT-005) for Gorlin Syndrome — up to 50 patients, primary endpoint complete clearance in ≥50% of target lesions at Week 10, building on prior 64% clinical clearance data (Source: https://t.co/1gkO6Xdy1S) 🔥

• 🔬💰 $22M non-dilutive financing already locked (pro forma cash ~$30M, >24-month runway, zero dilution) gives full flexibility to execute this registrational push without tapping equity markets (Source: https://t.co/0mn5AFErOh) 🚀

• 👀💣 Ultra-low float asymmetric setup + clean Phase 2 SKNJCT-003 data (55% histologic CR / 64% clinical clearance at 200µg with no serious adverse events) creates explosive volatility potential at the open (Source: https://t.co/x6VzXXXANT) 💥

• 🎯🌍 Watching the 50-day MA at $0.36 — could we see MDCX soar past this level toward new highs on continued momentum? 52-week high sits at $3.69 from current levels (Source: https://t.co/PG8WMKjIzZ) 🛡️

Disclaimer: https://t.co/5O5iV25rod

[巴里 @bstocks7]

SPONSORED

🔥 Nasdaq: $MDCX — $22M NON-DILUTIVE FINANCING + 55% PHASE 2 COMPLETE RESPONSE! LOW-FLOAT BIOPHARMA BREAKOUT SETUP! 💥🚀

• 📉💥 Ultra-low float asymmetric setup with massive volatility potential on catalyst flow — non-dilutive $22M financing extends runway >24 months with pro forma cash ~$30M (Source: https://t.co/x6VzXXXANT) ⚡

• 📰💰 Definitive $22M non-dilutive financing secured via secured promissory notes — zero shareholder dilution, supports aggressive FDA push through upcoming milestones (Source: https://t.co/0mn5AFErOh) 🚀

• 🔬🔥 Positive Phase 2 SKNJCT-003 data: 200µg D-MNA cohort hits 55% histologic complete response and 64% clinical clearance at Day 57 with no drug-related serious adverse events (Source: https://t.co/vZ2wmMH0Tz) ⚡

• 🛡️🏥 SkinJect® targets basal cell carcinoma & Gorlin Syndrome (~$2B market) — Orphan Drug Designation application filed; Teverelix® Phase 2b FDA-cleared for high-CV-risk prostate cancer with royalty reduced to 2% (Source: https://t.co/l5qetIiAll) 💥

• 🎯🌍 Dual-asset pipeline (~$8B combined addressable) + upcoming EOP2 FDA meeting, analyst targets to $9, and Reliant AI collaboration for capital-efficient development (Source: https://t.co/Sj9pxz5cho) 🛡️

Disclaimer: https://t.co/5O5iV25rod